PharmaCyte Biotech Ownership | Who Owns PharmaCyte Biotech?


OverviewFinancialsChart

PharmaCyte Biotech Ownership Summary


PharmaCyte Biotech is owned by 1.46% institutional investors, 5.74% insiders, and 92.80% retail investors. Citadel advisors is the largest institutional shareholder, holding 3.88% of PMCB shares. Vanguard US Total Market Shares ETF is the top mutual fund, with 1.71% of its assets in PharmaCyte Biotech shares.

PMCB Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockPharmaCyte Biotech1.46%5.74%92.80%
SectorHealthcare Stocks 35.42%11.83%52.76%
IndustryBiotech Stocks 35.46%11.78%52.76%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Citadel advisors359.55K3.88%$239.24K
Geode capital management195.66K2.11%$130.20K
Vanguard group74.92K1.10%$54.24K
Renaissance56.50K0.61%$37.59K
Xtx topco52.36K0.57%$34.84K
Susquehanna group, llp34.48K0.45%$53.45K
Virtu financial37.53K0.41%$25.00K
Northern trust35.60K0.38%$23.69K
Schonfeld strategic advisors27.01K0.29%$17.97K
Hrt financial lp24.74K0.27%$16.00K

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Ground swell capital11.53K0.02%$7.67K
Equitec proprietary markets22.23K0.01%$14.79K
Two sigma securities16.36K0.00%$10.89K
Virtu financial37.53K0.00%$25.00K
Xtx topco52.36K0.00%$34.84K
Renaissance56.50K0.00%$37.59K
Tower research capital llc (trc)4.89K0.00%$3.25K
Schonfeld strategic advisors27.01K0.00%$17.97K
Planning capital management100.000.00%$196.00
Commonwealth equity services10.31K-$6.86K

Top Buyers

HolderShares% AssetsChange
Citadel advisors359.55K-129.82K
Geode capital management195.66K-71.82K
Virtu financial37.53K0.00%37.53K
Xtx topco52.36K0.00%27.92K
Vanguard fiduciary trust23.45K-23.45K

Top Sellers

HolderShares% AssetsChange
K2 principal fund---209.27K
Hrt financial lp24.74K--158.06K
Sabby management---100.00K
Renaissance56.50K0.00%-37.54K
Dimensional fund advisors lp---20.30K

New Positions

HolderShares% AssetsChangeValue
Virtu financial37.53K0.00%37.53K$25.00K
Vanguard fiduciary trust23.45K-23.45K$15.60K
Ground swell capital11.53K0.02%11.53K$7.67K
Commonwealth equity services10.31K-10.31K$6.86K
Group one trading1.78K-1.78K$1.19K

Sold Out

HolderChange
Koesten, hirschmann & crabtree-1.00
Ifp advisors-1.00
Citigroup-1.00
Jones financial companies lllp-2.00
Aviso financial-12.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Mar 31, 202614-48.15%135,062-86.27%10.70%9-25.00%--100.00%
Dec 31, 202514-36.36%515,59719.05%718.68%6-33.33%2-50.00%
Sep 30, 202511-45.00%284,018-50.74%45.81%6-25.00%2-33.33%
Jun 30, 202521-12.50%576,4571.50%812.74%8-3-66.67%
Mar 31, 20252420.00%567,926-5.40%813.20%8300.00%912.50%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Vanguard US Total Market Shares ETF117.47K1.71%-
Vanguard Total Stock Mkt Idx Inv95.07K1.40%-24.46K
Fidelity Extended Market Index106.68K0.99%51.69K
Vanguard Institutional Extnd Mkt Idx Tr51.47K0.48%-
Spartan Total Market Index Pool E20.06K0.29%-
Fidelity Nasdaq Composite Index26.21K0.24%-
NT Ext Equity Mkt Idx Fd - L20.41K0.19%-
Northern Trust Extended Eq Market Idx20.41K0.19%16.39K
NT Ext Equity Mkt Index Fund - Lending20.41K0.19%-
Spartan Total Market Index Pool G20.06K0.19%-

Recent Insider Transactions


DateNameRoleActivityValue
Jan 07, 2026Silverman Joshua CEO and PresidentBuy$33.32K
Jan 06, 2026Silverman Joshua CEO and PresidentBuy$23.67K
Jan 05, 2026Silverman Joshua CEO and PresidentBuy$23.49K
Jan 07, 2026SCHECHTER JONATHAN-Buy$16.87K
Jan 06, 2026SCHECHTER JONATHAN-Buy$15.81K

Insider Transactions Trends


DateBuySell
2026 Q16-
2025 Q4--
2025 Q2--
2024 Q2--
2023 Q4--

PMCB Ownership FAQ


Who Owns PharmaCyte Biotech?

PharmaCyte Biotech shareholders are primarily institutional investors at 1.46%, followed by 5.74% insiders and 92.80% retail investors. The average institutional ownership in PharmaCyte Biotech's industry, Biotech Stocks , is 35.46%, which PharmaCyte Biotech falls below.

Who owns the most shares of PharmaCyte Biotech?

PharmaCyte Biotech’s largest shareholders are Citadel advisors (359.55K shares, 3.88%), Geode capital management (195.66K shares, 2.11%), and Vanguard group (74.92K shares, 1.10%). Together, they hold 7.10% of PharmaCyte Biotech’s total shares outstanding.

Does Blackrock own PharmaCyte Biotech?

BlackRock is not among the top 10 institutional shareholders of PharmaCyte Biotech.

Who is PharmaCyte Biotech’s biggest shareholder by percentage of total assets invested?

Ground swell capital is PharmaCyte Biotech’s biggest shareholder by percentage of total assets invested, with 0.02% of its assets in 11.53K PharmaCyte Biotech shares, valued at 7.67K$.

Who is the top mutual fund holder of PharmaCyte Biotech shares?

Vanguard US Total Market Shares ETF is the top mutual fund holder of PharmaCyte Biotech shares, with 1.71% of its total shares outstanding invested in 117.47K PharmaCyte Biotech shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools